NEDD8 Inhibition Overcomes CKS1B-Induced Drug Resistance by Upregulation of p21 in Multiple Myeloma

Clinical Cancer Research

Volumn 21, Issue 24, 2015, Pages 5532-5542

  Huang, Junwei ^a,b   Zhou, Yi ^a   Thomas, Gregory S ^a   Gu, Zhimin ^a   Yang, Ye ^a   Xu, Hongwei ^a   Tricot, Guido ^a   Zhan, Fenghuang ^a  

^a UNIVERSITY OF IOWA   (United States)

^b SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; NEDD8 PROTEIN; PEVONEDISTAT; PROTEIN CKS1B; PROTEIN P21; TUMOR PROTEIN; UNCLASSIFIED DRUG; ((1S,2S,4R)-4-(4-((1S)-2,3-DIHYDRO-1H-INDEN-1-YLAMINO)-7H-PYRROLO(2,3-D)PYRIMIDIN-7-YL)-2-HYDROXYCYCLOPENTYL)METHYL SULPHAMATE; ANTINEOPLASTIC AGENT; CKS1B PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLOPENTANE DERIVATIVE; NEDD8 PROTEIN, HUMAN; PYRIMIDINE DERIVATIVE; UBIQUITIN;

ARTICLE; CANCER RESISTANCE; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DRUG DETERMINATION; DRUG EFFICACY; DRUG POTENCY; HUMAN; HUMAN CELL; INHIBITION KINETICS; MULTIPLE MYELOMA; MULTIPLE MYELOMA CELL LINE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; UPREGULATION; ANTAGONISTS AND INHIBITORS; APOPTOSIS; CELL SURVIVAL; DRUG EFFECTS; DRUG RESISTANCE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; KAPLAN MEIER METHOD; METABOLISM; MORTALITY; PROTEIN DEGRADATION; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BORTEZOMIB; CDC2-CDC28 KINASES; CELL LINE, TUMOR; CELL SURVIVAL; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLOPENTANES; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KAPLAN-MEIER ESTIMATE; MULTIPLE MYELOMA; PROTEOLYSIS; PYRIMIDINES; SIGNAL TRANSDUCTION; UBIQUITINS;

EID: 84954139823     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-15-0254     Document Type: Article

References (34)

1. Howlader N NA, Krapcho M, Garshell J, Neyman N, Altekruse SF, Kosary CL, et al. (eds). SEER cancer statistics review, 1975-2010: National Cancer Institute; 2013.
2. Oerlemans R, Franke NE, Assaraf YG, Cloos J, van Zantwijk I, Berkers CR, et al. Molecular basis of bortezomib resistance: Proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein. Blood 2008;112:2489-99.
3. Franke NE, Niewerth D, Assaraf YG, van Meerloo J, Vojtekova K, van Zantwijk CH, et al. Impaired bortezomib binding tomutant beta5 subunit of the proteasome is the underlying basis for bortezomib resistance in leukemia cells. Leukemia 2012;26:757-68.
4. Spruck C, Strohmaier H, Watson M, Smith AP, Ryan A, Krek TW, et al. A CDK-independent function ofmammalian Cks1: Targeting of SCF(Skp2) to the CDK inhibitor p27Kip1. Mol Cell 2001;7:639-50.
5. Shi L, Wang S, Zangari M, Xu H, Cao TM, Xu C, et al. Over-expression of CKS1B activates both MEK/ERK and JAK/STAT3 signaling pathways and promotes myeloma cell drug-resistance. Oncotarget 2010;1:22-33.
6. Krishnan A, Nair SA, Pillai MR. Loss of cks1 homeostasis deregulates cell division cycle. J Cell Mol Med 2010;14:154-64.
7. Lee EK, Kim DG, Kim JS, Yoon Y. Cell-cycle regulator Cks1 promotes hepatocellular carcinoma by supportingNF-kappaB-dependent expression of interleukin-8. Cancer Res 2011;71:6827-35.
8. Wang X, Xu J, Ju S, Ni H, Zhu J, Wang H. Livin gene plays a role in drug resistance of colon cancer cells. Clin Biochem 2010;43:655-60.
9. Zolota VG, Tzelepi VN, Leotsinidis M, Zili PE, Panagopoulos ND, Dougenis D, et al. Histologic-type specific role of cell cycle regulators in non-small cell lung carcinoma. J Surg Res 2010;164:256-65.
10. Kitajima S, Kudo Y, Ogawa I, Bashir T, Kitagawa M, Miyauchi M, et al. Role of Cks1 overexpression in oral squamous cell carcinomas: Cooperation with Skp2 in promoting p27 degradation. Am J Pathol 2004;165:2147-55.
11. Slotky M, Shapira M, Ben-Izhak O, Linn S, Futerman B, Tsalic M, et al. The expression of the ubiquitin ligase subunit Cks1 in human breast cancer. Breast Cancer Res 2005;7:R737-44.
12. Nemec P, Zemanova Z, Greslikova H, Michalova K, Filkova H, Tajtlova J, et al. Gain of 1q21 is an unfavorable genetic prognostic factor for multiple myeloma patients treated with high-dose chemotherapy. Biol Blood Marrow Transplant 2010;16:548-54.
13. Hanamura I, Stewart JP, Huang Y, Zhan F, Santra M, Sawyer JR, et al. Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: Incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation. Blood 2006; 108:1724-32.
14. Chang H, Trieu Y, Qi X, Xu W, Stewart KA, Reece D. Bortezomib therapy response is independent of cytogenetic abnormalities in relapsed/refractory multiple myeloma. Leukemia Res 2007;31:779-82.
15. Shaughnessy JD Jr, Zhan F, Burington BE, Huang Y, Colla S, Hanamura I, et al. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood 2007;109:2276-84.
16. Chen MH, Qi C, Reece D, Chang H. Cyclin kinase subunit 1B nuclear expression predicts an adverse outcome for patients with relapsed/refractory multiple myeloma treated with bortezomib. Hum Pathol 2012; 43:858-64.
17. Saha A, Deshaies RJ. Multimodal activation of the ubiquitin ligase SCF by Nedd8 conjugation. Mol Cell 2008;32:21-31.
18. Zhan F, Huang Y, Colla S, Stewart JP, Hanamura I, Gupta S, et al. The molecular classification of multiple myeloma. Blood 2006;108:2020-8.
19. Mulligan G, Mitsiades C, Bryant B, Zhan F, Chng WJ, Roels S, et al. Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib. Blood 2007;109:3177-88.
20. Hideshima T, Bradner JE, Wong J, Chauhan D, Richardson P, Schreiber SL, et al. Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. Proc Natl Acad Sci U S A 2005;102:8567-72.
21. Escoubet-Lozach L, Lin IL, Jensen-Pergakes K, Brady HA, Gandhi AK, Schafer PH, et al. Pomalidomide and lenalidomide induce p21 WAF-1 expression in both lymphoma and multiple myeloma through a LSD1-mediated epigenetic mechanism. Cancer Res 2009;69: 7347-56.
22. Nawrocki ST, Kelly KR, Smith PG, Espitia CM, Possemato A, Beausoleil SA, et al. Disrupting protein NEDDylationwith MLN4924 is a novel strategy to target cisplatin resistance in ovarian cancer. Clin Cancer Res 2013;19: 3577-90.
23. Blank JL, Liu XJ, Cosmopoulos K, Bouck DC, Garcia K, Bernard H, et al. Novel DNA damage checkpoints mediating cell death induced by the NEDD8-activating enzyme inhibitor MLN4924. Cancer Res 2013;73: 225-34.
24. Barlogie B, Tricot G, Rasmussen E, Anaissie E, van Rhee F, Zangari M, et al. Total therapy 2 without thalidomide in comparison with total therapy 1: Role of intensified induction and posttransplantation consolidation therapies. Blood 2006;107:2633-8.
25. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003;348:2609-17.
26. McMillin DW, Jacobs HM, Delmore JE, Buon L, Hunter ZR, Monrose V, et al. Molecular and cellular effects of NEDD8-activating enzyme inhibition in myeloma. Mol Cancer Ther 2012;11:942-51.
27. Gu Y, Kaufman JL, Bernal L, Torre C, Matulis SM, Harvey RD, et al. MLN4924, an NAE inhibitor, suppresses AKT and mTOR signaling via upregulation of REDD1 in human myeloma cells. Blood 2014;123: 3269-76.
28. Xiong W,Wu X, Starnes S, Johnson SK, Haessler J, Wang S, et al. An analysis of the clinical and biologic significance of TP53 loss and the identification of potential novel transcriptional targets of TP53 in multiple myeloma. Blood 2008;112:4235-46.
29. Urashima M, Teoh G, Chauhan D, Hoshi Y, Ogata A, Treon SP, et al. Interleukin-6 overcomes p21WAF1 upregulation and G1 growth arrest induced by dexamethasone and interferon-gamma in multiple myeloma cells. Blood 1997;90:279-89.
30. Nardiello T, Jungbluth AA, Mei A, Diliberto M, Huang X, Dabrowski A, et al.MAGE-A inhibits apoptosis in proliferating myeloma cells through repression of Bax and maintenance of survivin. Clin Cancer Res 2011;17:4309-19.
31. Liontos M, KoutsamiM, SideridouM, Evangelou K, Kletsas D, Levy B, et al. Deregulated overexpression of hCdt1 and hCdc6 promotes malignant behavior. Cancer Res 2007;67:10899-909.
32. Lin JJ, Milhollen MA, Smith PG, Narayanan U, Dutta A. NEDD8-targeting drug MLN4924 elicits DNA rereplication by stabilizing Cdt1 in S phase, triggering checkpoint activation, apoptosis, and senescence in cancer cells. Cancer Res 2010;70:10310-20.
33. Lin HK, Chen Z, Wang G, Nardella C, Lee SW, Chan CH, et al. Skp2 targeting suppresses tumorigenesis by Arf-p53-independent cellular senescence. Nature 2010;464:374-9.
34. Jia L, Li H, Sun Y. Induction of p21-dependent senescence by an NAE inhibitor, MLN4924, as a mechanism of growth suppression. Neoplasia 2011;13:561-9.